-
EP4562011
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4562011
| EP4562011 - IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 14.05.2025 Database last updated on 21.03.2026 | |
| Former | The international publication has been made Status updated on 02.02.2024 | Most recent event Tooltip | 03.10.2025 | Change: Validation states | published on 05.11.2025 [2025/45] | 03.10.2025 | Change - extension states | published on 05.11.2025 [2025/45] | Applicant(s) | For all designated states Zymeworks BC Inc. Suite 800 - 114 East 4th Avenue Vancouver, BC V5T 1G4 / CA | [2025/23] | Inventor(s) | 01 /
GARNETT, Graham Albert Edwin Vancouver, British Columbia V5T 1G4 / CA | 02 /
HIRKALA-SCHAEFER, Truman Vancouver, British Columbia V5T 1G4 / CA | 03 /
BRANT, Michael G. Vancouver, British Columbia V5T 1G4 / CA | 04 /
COLOMBO, Raffaele Vancouver, British Columbia V5T 1G4 / CA | 05 /
DUAN, Zhuang Vancouver, British Columbia V5T 1G4 / CA | 06 /
BARNSCHER, Stuart Daniel Vancouver, British Columbia V5T 1G4 / CA | [2025/23] | Representative(s) | Grund, Martin, et al Grund Intellectual Property Group Patentanwälte und Solicitor PartG mbB Steinsdorfstraße 2 80538 München / DE | [2025/23] | Application number, filing date | 23844724.7 | 26.07.2023 | [2025/23] | WO2023CA51006 | Priority number, date | US202263392329P | 26.07.2022 Original published format: US 202263392329 P | [2025/23] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2024020684 | Date: | 01.02.2024 | Language: | EN | [2024/05] | Type: | A1 Application with search report | No.: | EP4562011 | Date: | 04.06.2025 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.02.2024 takes the place of the publication of the European patent application. | [2025/23] | Search report(s) | International search report - published on: | CA | 01.02.2024 | Classification | IPC: | C07D473/18, A61K31/52, A61K31/522, A61K47/50, A61K47/60, A61K47/65, A61K47/68, A61P35/00, C07D473/16, C07K5/00, C07K16/18, C07K16/30 | [2025/23] | CPC: |
C07D473/16 (EP,IL,KR);
C07D473/18 (EP,IL,KR);
A61K47/6879 (KR,US);
A61K31/52 (KR);
A61K47/65 (KR);
A61K47/6803 (EP,IL,US);
A61K47/6807 (KR);
A61K47/6851 (EP,IL,KR);
A61K47/6889 (US);
A61P35/00 (EP,IL,KR,US);
C07D487/04 (US);
C07D519/00 (EP,IL,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2025/23] | Title | German: | IMMUNMODULATORISCHE VERBINDUNGEN AUS PURIN, KONJUGATE DAVON UND VERFAHREN ZUR VERWENDUNG DAVON | [2025/23] | English: | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | [2025/23] | French: | COMPOSÉS DÉRIVÉS DE PURINE IMMUNOMODULATEURS, LEURS CONJUGUÉS ET LEURS PROCÉDÉS D'UTILISATION | [2025/23] | Entry into regional phase | 25.02.2025 | National basic fee paid | 25.02.2025 | Search fee paid | 25.02.2025 | Designation fee(s) paid | 25.02.2025 | Examination fee paid | Examination procedure | 25.02.2025 | Examination requested [2025/23] | 26.08.2025 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 28.07.2025 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X] US2009105212 (ISOBE YOSHIAKI et al.) [X] 1-60 * (entire document, abstract; examples 16, 17 and 23; para. [0217]; other examples; and claims) * | [X] CA2680397 (ASTRAZENECA AB et al.) [X] 1-60 * (entire document, abstract; example 48; paragraph[0067f; also examples 3, 9, 11, 12, 24, 32, 40-46, 48, 56-62, 70, 77, 86-3, 86-7, 87-2, 94, 95, 102 and 105; and claims) * | [X] WO2022040596 (AMBRX INC et al.) [X] 1-60 * (entire document, compounds 129, 130, 134; examples; claims) * | [X] WO2020168017 (AMBRX INC et al.) [X] 1-60 * (entire document, compounds 119, 120, 127, 129-130; examples; claims) * | [X] WO2017056494 (SUMITOMO DAINIPPON PHARMA CO LTD et al.) [X] 1-60 * (entire document, examples 1, 2, 3, 4 and 5 [Chem. 35, 40, 43, 50 and 54]; claims) * | [A] WO2017072662 (NOVARTIS AG et al.) [A] 1-60 * - cited in the application - (entire document) * | [X] NAKAMURA, T. ET AL.: "Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll- like receptor 7 agonists with high water solubility", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 3, 2013, pages 669 - 672, XP028962582, DOI: 10.1016/j.bmcl.2012.11.114 [X] 1, 7, 8, 11-12, 15, 34-38 * (entire document, incl. Table 2, compound 29) * DOI: http://dx.doi.org/10.1016/j.bmcl.2012.11.114 |